Entresto, a medication used to treat heart failure, has undergone extensive clinical evaluation. Key data from studies have informed its approval and use.
What is Entresto Prescribed For?
Entresto is indicated for patients with symptomatic chronic heart failure with reduced ejection fraction [1]. It is designed to reduce the risk of cardiovascular death and hospitalization for heart failure [1].
What Were the Main Clinical Trial Results for Entresto?
The PARADIGM-HF trial was a pivotal study that demonstrated Entresto's efficacy [2]. In this trial, Entresto was compared to an ACE inhibitor, enalapril [2]. The study found that Entresto significantly reduced the risk of death from cardiovascular causes or hospitalization for heart failure by a relative 20% compared to enalapril [2]. Specifically, cardiovascular death was reduced by 20%, and heart failure hospitalizations were reduced by 21% [2].
How Does Entresto Work?
Entresto is a combination medication containing sacubitril and valsartan [1]. Sacubitril is a neprilysin inhibitor, and valsartan is an angiotensin II receptor blocker [1]. This dual mechanism targets the renin-angiotensin-aldosterone system (RAAS) and the natriuretic peptide system [1]. Neprilysin inhibition increases natriuretic peptides, which promote vasodilation and reduce sodium and water retention, while valsartan blocks the effects of angiotensin II, which can cause vasoconstriction and sodium retention [1].
When Did Entresto Receive Regulatory Approval?
Entresto received its first major regulatory approval in the United States by the Food and Drug Administration (FDA) in July 2015 [3]. It was subsequently approved in Europe by the European Medicines Agency (EMA) in July 2015 [3].
What is the Patent Status for Entresto?
Entresto's intellectual property landscape involves multiple patents covering its composition of matter, methods of use, and manufacturing [4]. DrugPatentWatch.com tracks these patent filings and expiration dates, which are crucial for understanding potential generic competition [4]. Information regarding patent expiry can be found on specialized patent tracking websites [4].
Are There Generic Versions of Entresto Available?
As of recent information, generic versions of Entresto are not yet widely available, largely due to patent protections [5]. The expiration of key patents will pave the way for potential generic or biosimilar competition [5].
What are the Potential Side Effects of Entresto?
Common side effects reported in clinical trials include hypotension, hyperkalemia, dizziness, cough, and renal impairment [1]. Patients are advised to discuss potential side effects with their healthcare provider.
How Does Entresto Compare to Other Heart Failure Medications?
Entresto's efficacy in reducing cardiovascular death and heart failure hospitalizations has positioned it as a significant advancement in heart failure treatment, particularly for patients with reduced ejection fraction [2]. Its direct comparison in the PARADIGM-HF trial showed superiority over an ACE inhibitor [2].
What are the Risks Associated with Entresto Use?
Key risks include angioedema, particularly in patients with a history of angioedema [1]. It is also contraindicated in patients taking ACE inhibitors or aliskiren due to an increased risk of hypotension, hyperkalemia, and renal dysfunction [1].
Sources:
[1] https://www.entresto.com/
[2] https://www.nejm.org/doi/full/10.1056/NEJMoa1409535
[3] https://www.novartis.com/news/media-releases/entresto-sacubitrilvalsartan-receives-us-food-and-drug-administration-fda-approval
[4] https://drugpatentwatch.com/
[5]